Natália Prado da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Natália Prado da Silva has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Guilherme Diniz Tavares
Departamento de Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal de Juiz de Fora, R. José Lourenço Kelmer s/n, Campus Universitário, Juiz de Fora 36036-900, MG, Brazil
5 shared publications - Ana Carolina Morais Apolônio
Programa de Pós-Graduação em Odontologia na Faculdade de Odontologia da Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brasil
2 shared publications - Cícero Flávio Soares Aragão
Federal University of Rio Grande do Norte, Brazil
2 shared publications - Dayanne Lopes Porto
Federal University of Rio Grande do Norte, Brazil
2 shared publications - Fernanda Maria Pinto Vilela
Department of Pharmaceutical Sciences Federal University of Juiz de Fora Juiz de Fora Brazil
2 shared publications - Frederico Pittella
Federal University of Juiz de Fora (UFJF)
2 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 124
Dual drug release from Nanostructured Lipid Carriers promotes synergistic effects against melanoma cells
- 24 June 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 124
Open AccessDual drug release from Nanostructured Lipid Carriers promotes synergistic effects against melanoma cells
- 9 October 2025
- Published by Taylor & Francis in Nanomedicine
- Vol. 20 (22) , 2765-2789
Breakthroughs in the nanoparticle-mediated delivery of siRNA for breast cancer treatment
Although breast cancer treatments have improved, challenges like tumor heterogeneity and drug resistance remain. RNA interference (RNAi), especially through small interfering RNA (siRNA), is a promising strategy to silence specific genes and improve clinical outcomes. However, the clinical translation of siRNA has been limited by barriers related to stability, biodistribution, cellular uptake, among others. Nanoparticle-based delivery systems have emerged as transformative platforms to address these limitations, enhancing siRNA protection, targeting, and intracellular release. This review discusses the major breakthroughs in nanoparticle-mediated siRNA delivery for breast cancer treatment, focusing on how innovations in nanocarrier design have enhanced siRNA stability, targeting, and therapeutic efficacy. We highlight key characteristics in RNA interference mechanisms, the evolution of computational tools for optimizing siRNA design, and the approval of RNAi-based therapies that laid the foundation for oncologic applications. Special emphasis is given to the development of lipid, polymeric, and inorganic nanoparticles engineered for efficient siRNA delivery, their role in overcoming drug resistance when combined with conventional therapies, and the current progress of clinical trials against solid tumors. By integrating nanotechnology and RNAi, these breakthroughs offer new opportunities for precise, durable, and personalized strategies in breast cancer treatment, with the potential to transform the current therapeutic landscape.
- 9 October 2025
- Published by Taylor & Francis in Nanomedicine
- Vol. 20 (22) , 2765-2789
Breakthroughs in the nanoparticle-mediated delivery of siRNA for breast cancer treatment
Although breast cancer treatments have improved, challenges like tumor heterogeneity and drug resistance remain. RNA interference (RNAi), especially through small interfering RNA (siRNA), is a promising strategy to silence specific genes and improve clinical outcomes. However, the clinical translation of siRNA has been limited by barriers related to stability, biodistribution, cellular uptake, among others. Nanoparticle-based delivery systems have emerged as transformative platforms to address these limitations, enhancing siRNA protection, targeting, and intracellular release. This review discusses the major breakthroughs in nanoparticle-mediated siRNA delivery for breast cancer treatment, focusing on how innovations in nanocarrier design have enhanced siRNA stability, targeting, and therapeutic efficacy. We highlight key characteristics in RNA interference mechanisms, the evolution of computational tools for optimizing siRNA design, and the approval of RNAi-based therapies that laid the foundation for oncologic applications. Special emphasis is given to the development of lipid, polymeric, and inorganic nanoparticles engineered for efficient siRNA delivery, their role in overcoming drug resistance when combined with conventional therapies, and the current progress of clinical trials against solid tumors. By integrating nanotechnology and RNAi, these breakthroughs offer new opportunities for precise, durable, and personalized strategies in breast cancer treatment, with the potential to transform the current therapeutic landscape.
- 19 June 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 206, 107820
Poly(ε-caprolactone) nanocapsules coated with Chitosan optimize the antimicrobial activity of Tea Tree Oil and Azithromycin against oral pathogens
- 19 June 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 206, 107820
Poly(ε-caprolactone) nanocapsules coated with Chitosan optimize the antimicrobial activity of Tea Tree Oil and Azithromycin against oral pathogens
- 12 October 2024
- Published by Elsevier in Microbial Pathogenesis
- Vol. 196, 107006
Exploring the antimicrobial efficacy of tea tree essential oil and chitosan against oral pathogens to overcome antimicrobial resistance
- 12 October 2024
- Published by Elsevier in Microbial Pathogenesis
- Vol. 196, 107006
Exploring the antimicrobial efficacy of tea tree essential oil and chitosan against oral pathogens to overcome antimicrobial resistance
- 6 February 2024
- Published by Wiley in Journal of Surfactants and Detergents
- Vol. 27 (5) , 801-811
Unlocking the beauty benefits: Exploring biosurfactants from Scheffersomyces shehatae for cosmetics
As the cosmetic market continues to transform, innovative ingredients such as biosurfactants (BS) emerge as a fundamental step towards a generation of cosmetic products characterized by efficacy, safety, and environmental responsibility. In alignment with the global push towards natural, renewable, and non‐toxic materials, BS stands out as an interesting alternative to conventional synthetic surfactants. BS are a type of green surfactants and compared to synthetic surfactants derived from petroleum they are more biodegradable and have low or no toxicity. This work aimed to investigate the suitability of a biosurfactant extracted from the yeast Scheffersomyces shehatae (BS‐SS) to be used in cosmetic applications. The cytotoxicity of the BS‐SS was tested in fibroblast (L929) and keratinocyte (HaCaT) cell lines and the potential for ocular irritation was assessed by the hen's egg chorioallantoic membrane test (HET‐CAM). The cleaning efficiency of the BS‐SS was measured as the ability of make‐up removal in pig skin. Our results showed that the IC 50 values were 10.49 mg/mL for fibroblasts and 11.77 mg/mL for keratinocytes, and the biosurfactant did not result in hemorrhage, lysis, and coagulation damages in the chorioallantoic membrane, which classifies the biosurfactant solution as non‐irritant. Therefore, ocular toxicity and in vitro skin cell toxicity results showed that BS‐SS can be tolerable and safe for cosmetic purposes. BS‐SS featured promising cleaning properties, similar to the cleansing activity of the 1% SDS solution and of micellar water for lipstick and foundation products. In conclusion, the results indicate its potential use in cosmetic applications.
- 6 February 2024
- Published by Wiley in Journal of Surfactants and Detergents
- Vol. 27 (5) , 801-811
Unlocking the beauty benefits: Exploring biosurfactants from Scheffersomyces shehatae for cosmetics
As the cosmetic market continues to transform, innovative ingredients such as biosurfactants (BS) emerge as a fundamental step towards a generation of cosmetic products characterized by efficacy, safety, and environmental responsibility. In alignment with the global push towards natural, renewable, and non‐toxic materials, BS stands out as an interesting alternative to conventional synthetic surfactants. BS are a type of green surfactants and compared to synthetic surfactants derived from petroleum they are more biodegradable and have low or no toxicity. This work aimed to investigate the suitability of a biosurfactant extracted from the yeast Scheffersomyces shehatae (BS‐SS) to be used in cosmetic applications. The cytotoxicity of the BS‐SS was tested in fibroblast (L929) and keratinocyte (HaCaT) cell lines and the potential for ocular irritation was assessed by the hen's egg chorioallantoic membrane test (HET‐CAM). The cleaning efficiency of the BS‐SS was measured as the ability of make‐up removal in pig skin. Our results showed that the IC 50 values were 10.49 mg/mL for fibroblasts and 11.77 mg/mL for keratinocytes, and the biosurfactant did not result in hemorrhage, lysis, and coagulation damages in the chorioallantoic membrane, which classifies the biosurfactant solution as non‐irritant. Therefore, ocular toxicity and in vitro skin cell toxicity results showed that BS‐SS can be tolerable and safe for cosmetic purposes. BS‐SS featured promising cleaning properties, similar to the cleansing activity of the 1% SDS solution and of micellar water for lipstick and foundation products. In conclusion, the results indicate its potential use in cosmetic applications.
- Open Access
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 58
Cecropia pachystachya Trécul: a promising ingredient for skin-whitening cosmetics
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 58
Open AccessCecropia pachystachya Trécul: a promising ingredient for skin-whitening cosmetics